<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04293783</url>
  </required_header>
  <id_info>
    <org_study_id>Reg. Sperim. 244/19</org_study_id>
    <nct_id>NCT04293783</nct_id>
  </id_info>
  <brief_title>Randomized Double-blind Clinical Trial With L.Reuteri Supplementation in Children With Autism Spectrum Disorder</brief_title>
  <official_title>Efficacy of Lactobacillus Reuteri in Managing Social Deficits in Children With Autistic Spectrum Disorder: a Randomized Clinical Trial With Evaluation of Gut Microbiota and Metabolomics Profiles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rome Tor Vergata</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rome Tor Vergata</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the effects of a 6-months probiotic supplementation on
      behavioral profiles, microbiota and metabolic profiles, inflammatory biomarkers,
      gastrointestinal disturbances, in children with Autism Spectrum Disorders (ASD) with or
      without GI symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autism Spectrum Disorder (ASD) is a condition that includes social deficits, repetitive
      behaviors and language difficulties; its prevalence continues to increase worldwide, however,
      there are no medication for the core symptoms of this disorder. In addition to these core
      symptoms, children with ASD are 3.5 times more likely to suffer from gastrointestinal issues
      than children without developmental disorders. Moreover, GI problems have been associated
      with changes in the microbial communities inhabiting the gut of ASD individuals.

      Studies in animal models have suggested that the gut microbes can modulate central nervous
      system-driven behaviors.

      In 2019, a research group (Buffington et al.) found that a specific strain (L. Reuteri PTA)
      rescues the deficit in social interaction-induced VTA plasticity in ASD mouse, enhancing the
      salience and rewarding value of social stimuli.

      These data support the idea that microbial therapies could ameliorate specific endophenotypes
      associates with ASD.

      Aim of the study The aim of this pilot study is to determine the possible effects of
      supplementation with a specific probiotic strain (L. Reuteri ATCC PTA 6475) in ASD children
      on the core deficits of the disorder, the social behavior. A secondary aim is to evaluate the
      effects of probiotic supplementation on specific GI symptoms, and repetitive, dysfunctional
      behaviors, widely described in ASD children. Finally, the investigators will evaluate gut
      microbiota (fecal and salivary samples) and metabolomics (urinary samples) profiles
      differences before and after the supplementation.

      Methods and participants Double blind randomized, placebo-controlled trial, with a
      nutritional supplement, with two parallel arms, an allocation ratio of 1:1, and a superiority
      framework.

      The investigators aim to enroll 80 patients. A detailed informed consent will be given and
      and both parents will sign it before the start of the data collection.

      The participants, after a first evaluation, will be divided into 2 groups; each arm will be
      blind randomized 1:1 to regular diet with a specific probiotic strain (L. Reuteri ATCC PTA
      6475) or with placebo for 6 months.

      After randomization the investigators will explain how to take the product and the first dose
      will be administered.

      During the study the child is not allowed to take other probiotics. The type of
      neurologic/rehabilitation therapy ongoing at T0 cannot be changed until the study is
      finished.

      Study Product Test product chewable tablets: 1x108 CFU Lactobacillus reuteri DSM 17938 +
      1x108 CFU Lactobacillus reuteri ATCC PTA 6475 (together 2x108 CFU) Placebo chewable caps:
      identical in shape and taste to the test product without the Lactobacillus reuteri components
      Both study products are delivered in identical containers and labelled as XXX. Dosing: Two
      tablets/cps once a day.

      Assessment

      At the time of enrollment, each participant will undergo a comprehensive neuropsychological
      and biochemical evaluation, in order to establish the baseline of the primary and secondary
      outcome measures. A detailed Case Record Forms (CRF) containing all data pertinent to the
      study will be prepared.

      At T0 the investigators will also collect blood, urinary salivary and fecal sample from each
      participant in order to perform biochemical, microbiological and metabolomics evaluation. The
      parents have to fill out questionnaire about dietary habits in a 5 day-diary.

      After three months from the enrollment (T1), each child will undergo a second evaluation with
      some clinical and biological measures.

      At the end of the study, six months from baseline, the investigators will perform another
      complete assessment through the same clinical, biochemical and neuropsychological evaluation
      performed at T0, to evaluate the possible changes in (1) autism symptoms severity; (2)
      affective and behavioral comorbid symptoms; (3) GI symptoms; (4) plasmatic, urinary and fecal
      biomarkers related to abnormal intestinal/inflammatory function. At T2, urinary salivary, and
      fecal sample will be also collected from each participant in order to perform microbiological
      and metabolomics evaluation.

      All children recruited will undergo the evaluation at Child Neurology and Psychiatry unit,
      Policlinico Tor Vergata, Rome, Italy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blind randomized, parallel-group, placebo-controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Placebo chewable caps are identical in shape and taste to the test product, without the Lactobacillus reuteri components Both study products are delivered in identical containers and labelled as XXX.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in severity level of ASD symptomatology</measure>
    <time_frame>6 months</time_frame>
    <description>Delta of scores at Autism Diagnostic Observation Schedule-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Microbiome Profile</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Characterization of the fecal and salivary microbiota by using a metagenomic approach (amplification and sequencing of a portion of the bacterial 16S rRNA) gene. A special focus is to evaluate if there is dysbiosis, if the supplementation rescues the dysbiosis and if these changes are correlated with the gastrointestinal and behavioral symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in GI symptoms</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Delta of scores at GSRS (Gastrointestinal Symptoms Rating Scale). Higher scores are related to greater severity of symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ASD symptomatology: problematic behaviors</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Delta of scores at ABC (Aberrant Behavior Checklist), a 58 item scale. Higher scores are related to greater severity of symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ASD symptomatology: repetitive behaviors</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Delta of scores at RBS-R (Repetitive Behavior Scale-Revised), a 43 item scale. Higher scores are related to greater severity of symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Adaptive Functioning</measure>
    <time_frame>6 months</time_frame>
    <description>Delta of scores at Adaptive Behavior Assessment System-II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in global ASD symptomatology</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Delta of scores at SRS (Social Responsiveness Scale). Higher scores are related to greater severity of symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Behavioral Profiles</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Delta of scores at CBCL (Child Behavior CheckList)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Parental Stress</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Delta of scores at PSI (Parenting Stress Index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Metabolomic Profile</measure>
    <time_frame>6 months</time_frame>
    <description>Urinary samples collected for NMR analysis. Metabolomics profiles will be directed at biochemical processes such as neurotransmitter metabolism, gastrointestinal alterations or dysbiosis, and mitochondrial dysfunction). Furthermore, the effect of probiotic administration on the metabolome will be investigated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Inflammatory Profile</measure>
    <time_frame>6 months</time_frame>
    <description>Blood sample collected to evaluate changes in inflammatory profile (zonulin, IL-17 profile)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>L.Reuteri</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lactobacillus reuteri DSM 17938 + Lactobacillus reuteri ATCC PTA 6475 two tablet by mouth 1 time per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo two tablet by mouth 1 times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L.Reuteri</intervention_name>
    <description>daily supplementation with two tablet for six months</description>
    <arm_group_label>L.Reuteri</arm_group_label>
    <other_name>Gastrus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>daily supplementation with two tablet for six months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Autism Spectrum Disorder (DSM-5 criteria diagnosis)

        Exclusion Criteria:

          -  neurological syndromes (that explain autism symptoms)

          -  coeliac disease

          -  other organic GI disorder

          -  special diet.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mazzone Luigi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rome Tor Vergata</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francavilla Ruggiero, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bari</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberta Abate, MD</last_name>
    <phone>3283211755</phone>
    <phone_ext>+39</phone_ext>
    <email>robiabate@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luigi Mazzone, MD, PhD</last_name>
    <phone>3395969516</phone>
    <phone_ext>+39</phone_ext>
    <email>gigimazzone@yahoo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Bari</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Rome Tor Vergata</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Abate, MD</last_name>
      <phone>3283211755</phone>
      <phone_ext>+39</phone_ext>
      <email>robiabate@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Luigi Mazzone, MD, PhD</last_name>
      <phone>3395969516</phone>
      <phone_ext>+39</phone_ext>
      <email>gigimazzone@yahoo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Luigi Mazzone, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberta Abate, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucrezia Arturi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martina Siracusano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Sgritta M, Dooling SW, Buffington SA, Momin EN, Francis MB, Britton RA, Costa-Mattioli M. Mechanisms Underlying Microbial-Mediated Changes in Social Behavior in Mouse Models of Autism Spectrum Disorder. Neuron. 2019 Jan 16;101(2):246-259.e6. doi: 10.1016/j.neuron.2018.11.018. Epub 2018 Dec 3.</citation>
    <PMID>30522820</PMID>
  </reference>
  <reference>
    <citation>Vuong HE, Yano JM, Fung TC, Hsiao EY. The Microbiome and Host Behavior. Annu Rev Neurosci. 2017 Jul 25;40:21-49. doi: 10.1146/annurev-neuro-072116-031347. Epub 2017 Mar 8. Review.</citation>
    <PMID>28301775</PMID>
  </reference>
  <reference>
    <citation>Schieve LA, Gonzalez V, Boulet SL, Visser SN, Rice CE, Van Naarden Braun K, Boyle CA. Concurrent medical conditions and health care use and needs among children with learning and behavioral developmental disabilities, National Health Interview Survey, 2006-2010. Res Dev Disabil. 2012 Mar-Apr;33(2):467-76. doi: 10.1016/j.ridd.2011.10.008. Epub 2011 Nov 24.</citation>
    <PMID>22119694</PMID>
  </reference>
  <reference>
    <citation>Lussu M, Noto A, Masili A, Rinaldi AC, Dess√¨ A, De Angelis M, De Giacomo A, Fanos V, Atzori L, Francavilla R. The urinary (1) H-NMR metabolomics profile of an italian autistic children population and their unaffected siblings. Autism Res. 2017 Jun;10(6):1058-1066. doi: 10.1002/aur.1748. Epub 2017 Mar 11.</citation>
    <PMID>28296209</PMID>
  </reference>
  <reference>
    <citation>Indrio F, Di Mauro A, Riezzo G, Civardi E, Intini C, Corvaglia L, Ballardini E, Bisceglia M, Cinquetti M, Brazzoduro E, Del Vecchio A, Tafuri S, Francavilla R. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial. JAMA Pediatr. 2014 Mar;168(3):228-33. doi: 10.1001/jamapediatrics.2013.4367.</citation>
    <PMID>24424513</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>March 1, 2020</last_update_submitted>
  <last_update_submitted_qc>March 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rome Tor Vergata</investigator_affiliation>
    <investigator_full_name>Luigi Mazzone</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Probiotic</keyword>
  <keyword>Gut-Brain axis</keyword>
  <keyword>L. Reuteri</keyword>
  <keyword>Social Behavior</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Metabolome</keyword>
  <keyword>Inflammatory Profile</keyword>
  <keyword>Gastrointestinal Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all collected IPD</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>starting 6 months after publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

